Print

Email story

Comment

Letter to the editor

Cervical cancer test better

A study finds the HPV test is much more accurate than a Pap smear.

NEW YORK - A relatively new screening test was about twice as accurate as the traditional Pap smear at spotting cervical cancer, according to the first rigorous study of the test in North America.

The new test could replace the 50-year-old Pap in a matter of years, experts say. And there's a bonus for women: They won't need a screening test as often.

The HPV test, which looks for the virus that causes cervical cancer, correctly spotted 95 percent of the cancers. The Pap test, which checks for abnormal cells under a microscope, only found 55 percent, according to researchers at McGill University in Montreal, who published their findings in today's New England Journal of Medicine.

"We've had the Pap test for over 50 years, and it's high time it be replaced by technology that's more robust," said Eduardo Franco, director of McGill's division of cancer epidemiology, who led the study.

HPV, or human papilloma virus, is a common sexually transmitted disease. The HPV test looks for the high-risk viruses that can cause cervical cancer if the infection persists. Like the Pap, it uses cells scraped from the cervix, the lower part of the uterus.

The HPV test has been available in the United States since 2000 and was first used for inconclusive Pap tests. Now women over 30 can get a HPV test - but only along with a Pap - and wait three years to be tested again if both tests are negative.

More recently, scientists have been studying whether the HPV test can be used alone and whether it can prolong the intervals between exams.

Debbie Saslow, director of breast and gynecologic cancer for the American Cancer Society, said evidence from a number of studies supports using the HPV test in place of a Pap.

"Overall, I don't think there's any doubt that HPV testing has a lot of advantages over the Pap test," she said.

Saslow said there are still issues to be resolved, and federal approval needed, but "it's definitely coming." She said experts expect that to happen sometime in the next decade.

The HPV test is more expensive: In the United States, Medicare pays about $50 for the HPV test and $15 to $28 for a Pap test.

Some of the researchers have received fees or grants from drugmakers including Merck Frosst Canada Ltd., a subsidiary of Merck & Co., which makes a cervical cancer vaccine. One has stock in Digene Corp., which developed the only approved HPV test.

[Last modified October 18, 2007, 01:21:39]